Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.

Stein, Eytan M; DiNardo, Courtney D; Pollyea, Daniel A; Fathi, Amir T; Roboz, Gail J; Altman, Jessica K; Stone, Richard M; DeAngelo, Daniel J; Levine, Ross L; Flinn, Ian W; Kantarjian, Hagop M; Collins, Robert; Patel, Manish R; Frankel, Arthur E; Stein, Anthony; Sekeres, Mikkael A; Swords, Ronan T; Medeiros, Bruno C; Willekens, Christophe; Vyas, Paresh; Tosolini, Alessandra; Xu, Qiang; Knight, Robert D; Yen, Katharine E; Agresta, Sam; de Botton, Stephane; Tallman, Martin S.
Blood; 130(6): 722-731, 2017 08 10.
Artigo em Inglês | MEDLINE | ID: mdl-28588020